Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.
PD-L1
companion diagnostics
macrophage
non-small-cell lung cancer
renal cell carcinoma
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
23
03
2022
received:
24
09
2021
accepted:
20
04
2022
pubmed:
29
5
2022
medline:
14
9
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
Programmed death (PD)-1/PD-ligand 1 (PD-L1) antibodies have shown an intense clinical effect in some patients with PD-L1
Identifiants
pubmed: 35633190
doi: 10.1111/cas.15442
pmc: PMC9459416
doi:
Substances chimiques
Antibodies
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3255-3266Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18J01441
Organisme : Japan Society for the Promotion of Science
ID : 19K07459
Informations de copyright
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Clin Oncol. 2020 Dec 10;38(35):4138-4148
pubmed: 33026938
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Sci. 2016 Nov;107(11):1696-1704
pubmed: 27564404
J Pathol. 2021 Jul;254(4):374-383
pubmed: 33846997
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Immunobiology. 2017 Apr;222(4):651-657
pubmed: 28017495
JAMA Oncol. 2020 Oct 1;6(10):1571-1580
pubmed: 32880601
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cancer Sci. 2022 Sep;113(9):3255-3266
pubmed: 35633190
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Cancer Res. 2004 Feb 1;64(3):1140-5
pubmed: 14871849
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
Clin Exp Dermatol. 2009 Oct;34(7):793-9
pubmed: 19438554
Cancer Sci. 2019 Sep;110(9):2711-2721
pubmed: 31294893
Front Immunol. 2019 Jul 17;10:1654
pubmed: 31379850
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cytokine Growth Factor Rev. 2019 Aug;48:24-31
pubmed: 31296363
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Lancet. 2001 Sep 22;358(9286):966-70
pubmed: 11583750
Cancer Immunol Immunother. 2019 Feb;68(2):201-211
pubmed: 30357491
J Clin Oncol. 2001 Feb 1;19(3):812-23
pubmed: 11157035
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Exp Med. 2016 Dec 12;213(13):2835-2840
pubmed: 27903604